Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia trial XI (MRC UKALLXI)

Leukemia

Volumn 12, Issue 8, 1998, Pages 1249-1255

  Hann, I M ^a   Richards, S M ^b   Eden, O B ^c   Hill, F G H ^d  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Acute lymphoblastic leukaemia (ALL); Children; Immunophenotype; Prognosis

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD LEUKEMIA; FEMALE; GENDER; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; T CELL LEUKEMIA;

EID: 0031875371     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401093     Document Type: Article

References (14)

1. Greaves MF, Janossy G, Peto J, Kay H. Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br J Haematol 1981; 48: 179-197.
2. Kumar S, Carr T, Evans DIK, Morris-Jones P, Hann IM. Prognostic significance of cell surface markers in childhood ALL. J Clin Lab Haematol 1979; 1: 121-128.
3. Fletcher JA, Kimball VM, Lynch E et al. Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukaemia. Blood 1989; 74: 2130-2135.
4. Raimondi SC, Behm FG, Robertson PK et al. Cytogenetics of pre-B-cell acute lymphoblastic leukaemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 1990; 8: 1380-1388.
5. Reiter A, Schrappe M, Ludwig WD et al. Favourable outcome of B-cell acute lymphoblastic leukaemia in childhood. A report of three consecutive studies of the BFM group. Blood 1992; 80: 2471-2478.
6. Janossy G, Coustan-Smith E, Campana D. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukaemia: a study of 500 cases. Leukemia 1989; 3: 170-181.
7. Campana D, Hansen-Hagge TE, Matutes E et al. Phenotypic, genotypic, cytochemical and ultrastructural characterisation of acute undifferentiated leukaemia. Leukemia 1990; 4: 620-624.
8. Hann IM, Eden OB, Barnes J, Pinkerton CR. MACHO chemotherapy for stage IV B cell lymphoma and B cell ALL of childhood. Br J Haematol 1990; 76: 364-369.
9. Bowman WP, Shuster JJ, Cook B et al. Improved survival for children with B-cell acute lymphoblastic leukaemia and stage IV small noncleaved-cell lymphoma: a Paediatric Oncology Group Study. J Clin Oncol 1996; 14: 1252-1261.
10. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK MRC Trial UKALL X. Lancet 1995; 345: 143-148.
11. Peto R, Pike MC, Armitage P et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient (II): analysis and examples. Br J Cancer 1997; 35: 1-39.
12. Lilleyman JS, Hann IM, Stevens RF et al. Cytomorphology of childhood lymphoblastic leukaemia: a prospective study of 2,000 patients. Br J Haematol 1993; 81: 52-57.
13. Campana D, Coustan-Smith E, Behm FG. The definition of remission in acute leukaemia with immunological techniques. Bone Marrow Transplant 1991; 8: 429-437.
14. Van Dongen JJM, Breit TM, Adriaansen HJ et al. Detection of minimal residual disease in acute leukaemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992; 6 (Suppl. 1): 47-59.